Immunohistochemistry (IHC) tests

HSL-AD has an extensive library of antibodies for the immunochemical characterisation of cancer samples. These probes can detect antigens that arise de novo, or are upregulated.

Using immunohistochemistry, cancer subtypes can be determined, a cancer can be diagnosed as malignant or benign, the cell type and origin of a metastasis can be identified, and drug efficacy can be tracked.

HSL-AD participates in external quality assurance (EQA) across various modules through UK NEQAS ICC & ISH, NordiQC, and GenQA. For tests not covered by conventional EQA schemes within the previous 12 months, an alternative approach to EQA is implemented to ensure ongoing quality assessment.

Please use the search box below to filter this list